PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Brexit Bombshell: Turbulence Ahead for Pharma

Realizing the Potential of Asia-Pacific

The Push for Story-Driven Engagement

Pharm Exec eBooks Available as Apps

Lead Story
"Sunshine" in the UK: Disclosure Database Launched
The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has brought some sunlight to the UK, if dappled, writes Leela Barham
/Read more/
Brexit
How One Pollster Correctly Predicted Brexit
Only one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports
/Read more/
Calendar
/ September 22–23: Real World Evidence 2016 /
Philadelphia, USA
/ November 16–17: Global Compliance Congress for Life Sciences /
London, UK
/ January 26–27, 2017: 12th Annual Biosimilars Summit /
Alexandria, VA, USA
/ February 22–23, 2017: Speaker Programs 2017 /
Philadelphia, USA
R&D
Clinical Trials and Anonymization: New EMA Guidelines
Dave Handelsman offers a smart approach to dealing with the EMA's new guidelines on the anonymization of clinical trial data
/Read more/
Digital Marketing
Microsoft Means Business with LinkedIn
Last month Microsoft bought LinkedIn. What does this mean for pharm execs using the platform? Peter Houston takes a look
/Read more/
 
Industry update
//The Romaco Group appointed Dirk Bauernfeind as Managing Director of Romaco Pharmatechnik GmbH (Karlsruhe, Germany). He will share the responsibility for the company with Carsten Strenger, CFO/COO of the Romaco Group. As of July 2016, Paulo Alexandre will concentrate on his core function as CEO of the Romaco Group.//Umecrine Cognition AB (Stockholm, Sweden) announced that Dr. Bruce Scharschmidt has been appointed as a new member of its board of directors and Senior Development Adviser.//Sequana Medical AG (Zurich, Switzerland) appointed Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, as Chairman of the Board of Directors.//Envigo (Huntingdon, UK) announced that its Board of Directors appointed Dr. Adrian Hardy as President and Chief Executive Officer, and that he will join the Company's Board of Directors. Dr. Hardy joined Envigo in 2002.//
 
update my profile / advertise with us / print subscribe / digital subscribe / visit pharmexec.com